Neurocrine Announces Initiation of a Long-Term Phase II Clinical Study of VMAT2 Inhibitor Valbenazine in Tourette Syndrome
This study is an open-label, fixed-dose, study of up to 180 male and female patients with Tourette syndrome, consisting of up to 90 children and adolescents and up to 90 adults. The primary purpose of the study is to assess the long-term safety and tolerability of valbenazine. Enrollment in this long-term study is limited to subjects who have completed either the ongoing placebo-controlled T-Force GREEN or T-Forward studies. Patients will receive once-daily dosing during a twenty-four week treatment period to assess the safety and tolerability of valbenazine.
"We are very pleased with the conduct of our two ongoing placebo-controlled Phase II studies in Tourette syndrome. The clinical sites are successfully reaching out to patients and families for enrollment and the subject characteristics are exactly in line with our expectations," said
Long-Term Phase II Study Design
The study is an open-label, fixed-dose, Phase II study to evaluate the safety and tolerability of NBI-98854 in up to 180 patients with Tourette syndrome. The study will enroll up to 90 pediatric patients and 90 adult patients with moderate to severe Tourette syndrome. Enrollment in this study is restricted to subjects who have completed either the T-Force GREEN or T-Forward Phase II studies. Evaluation of subjects in the study consists of up to three weeks of screening followed by twenty-four weeks of dosing, then followed by four weeks off-drug at approximately 60 study centers in the United States. Once-daily fixed doses of valbenazine will be evaluated for safety and tolerability via standard clinical laboratory tests, monthly physician examinations and safety scale assessments. The dosing regimen for this study is consistent with the two ongoing Phase II studies; T-Force GREEN and T-Forward. During the study, the symptoms of Tourette syndrome will be evaluated utilizing the Yale Global Tic Severity Scale, the Rush Video-Based Tic Rating Scale, Premonitory Urge for Tics Scale as well as Clinical Global Impression scales.
About T-Force GREEN and T-Forward Studies
The T-Force GREEN and T-Forward studies are ongoing multicenter, randomized, double-blind, placebo-controlled, multi-dose, parallel group, Phase II studies to evaluate the safety, tolerability and efficacy of valbenazine. Once-daily fixed doses of NBI-98854 are being evaluated vs. placebo in a 1:1:1 randomization. These studies will each enroll up to 90 patients with moderate to severe Tourette syndrome, the T-Force GREEN is enrolling children and adolescents and the T-Forward is enrolling adults. The primary endpoint of each of these studies is the change from baseline of the Yale Global Tic Severity Scale between placebo and active treatment groups at the end of placebo-controlled treatment. Tourette symptoms will also be evaluated via the Rush Video-Based Tic Rating Scale, Premonitory Urge for Tics Scale as well as Clinical Global Impression scales, among others.
About Tourette Syndrome
Tourette syndrome is a neurological disorder that consists of rapid, non-rhythmic stereotyped motor and vocal tics. Motor tics are typically characterized by facial grimacing, head jerks, extremity movements and other dystonic movements. Vocal tics typically include grunting, throat clearing, and repeating words and phrases. The average age of onset for Tourette syndrome is six years, with symptoms reaching their peak severity at approximately age ten. Tourette syndrome is more commonly diagnosed in males than females and may be associated with attention deficit hyperactivity disorder and obsessive compulsive disorder. There are approximately 400,000 people with Tourette syndrome in
About Valbenazine
VMAT2 is a protein concentrated in the human brain that is primarily responsible for re-packaging and transporting monoamines (dopamine, norepinephrine, serotonin, and histamine) in pre-synaptic neurons. Valbenazine (NBI-98854), developed in the Neurocrine laboratories, is a novel, highly-selective VMAT2 inhibitor that modulates dopamine release during nerve communication, while at the same time having minimal impact on the other monoamines, thereby reducing the likelihood of "off-target" side effects. Valbenazine is designed to provide low, sustained, plasma and brain concentrations of active drug to minimize side effects associated with excessive monoamine depletion.
Modulation of neuronal dopamine levels in diseases such as tardive dyskinesia, Tourette syndrome, Huntington's chorea, schizophrenia, and tardive dystonia, which are characterized, in part, by a hyperdopaminergic state, should provide symptomatic benefits for patients with these diseases.
Neurocrine has received Breakthrough Therapy Designation from the
About
In addition to historical facts, this press release may contain forward-looking statements that involve a number of risks and uncertainties. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with Neurocrine's business and finances in general, as well as risks and uncertainties associated with NBI-98854 (valbenazine) development. Specifically, the risks and uncertainties the Company faces include risks that valbenazine development activities may not be completed on time or at all; risks that NBI-98854 development activities may be delayed for regulatory or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that valbenazine is safe, tolerable or effective, or may not be predictive of real-world results or of results in subsequent clinical trials; risks that valbenazine regulatory submissions may not occur or be submitted in a timely manner; risks that valbenazine may not obtain regulatory approval for tardive dyskinesia, Tourette syndrome, or at all, or that the
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/neurocrine-announces-initiation-of-a-long-term-phase-ii-clinical-study-of-vmat2-inhibitor-valbenazine-in-tourette-syndrome-300305753.html
SOURCE
Investor Relations, (858) 617-7600